Jakub Krejcik

Odense, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies.

Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies.

Journal: Frontiers in immunology

Published: April 02, 2026

Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia.

Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences

Published: September 30, 2024

Role of NK Cells in Progression and Treatment of Multiple Myeloma.

Role of NK Cells in Progression and Treatment of Multiple Myeloma.

Journal: Frontiers in bioscience (Landmark edition)

Published: August 20, 2024

Harnessing the Immune System to Fight Multiple Myeloma.

Harnessing the Immune System to Fight Multiple Myeloma.

Journal: Cancers

Published: July 21, 2021

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Journal: British journal of haematology

Published: April 02, 2019

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma.

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma.

Journal: Oncotarget

Published: August 28, 2018

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: June 22, 2018

Daratumumab for the Treatment of Multiple Myeloma.

Daratumumab for the Treatment of Multiple Myeloma.

Journal: Frontiers in immunology

Published: February 21, 2018

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 13, 2017

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Journal: Blood

Published: July 07, 2016

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Journal: Blood

Published: December 15, 2015

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Journal: The New England journal of medicine

Published: August 27, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026